St Jude to buy back $250m in shares
This article was originally published in Clinica
St. Jude Medical announced on Monday (Feb 25) it is to repurchase $250m of its common stock. The company said any shares acquired will be available for general corporate purposes, including offsetting dilution associated with stock option and other equity-based employee benefit plans. As of December 29 2007, St Jude had around 343 million shares outstanding.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.